Townsend Richard Nolan's Form 4 filing
Lexeo Therapeutics, Inc. (LXEO) · filed Aug 20, 2025
- Accession no.
- 0001415889-25-022473
- Filed
- Aug 20, 2025
- Trade date
- Aug 18, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 0 derivative transactions. Open-market sales total $12.8K. It was filed 2 days after the trade.
This filing was later replaced by the amendment 0001415889-25-024104 (Sep 10, 2025). Trade tables on this site use the amended version.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Townsend Richard NolanCIK 0001995218 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 18, 2025 | Common Stock | SSaleDisposed | −2,735 | $4.67 | −$12,772.45 | 220,058 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.